Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review

Imagem de Miniatura
Arquivos
art_TORELLI_Eltrombopag_for_Adults_and_Children_with_ImmuneRefractory_Thrombocytopenic_2023.PDF (3.53 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
TORELLI, Danielle Francisco Honorato de Barros
OLIVEIRA, Crystian Bitencourt Soares
NAI, Gisele Alborghetti
PRESTES-CARNEIRO, Luiz Euribel
Citação
JOURNAL OF CLINICAL MEDICINE, v.12, n.12, article ID 3872, 12p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Eltrombopag is an agonist that binds to the membrane-bound domain of the thrombopoietin receptor used in immune thrombocytopenic purpura (ITP). We conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of eltrombopag in adults and children with refractory ITP. Adults who received eltrombopag had a significantly better platelet response (relative risk [RR], 3.65; 95% confidence interval [CI], 2.39-5.55), but there were no differences in the incidence of bleeding (RR, 0.8; 95% CI, 0.52-1.22) and adverse effects (RR, 0.99; 95% CI, 0.55-1.78) compared with the placebo. In children, there was no difference between eltrombopag and placebo for a platelet response >50,000/mm(3) (RR, 3.93; 95% CI, 0.56-27.79) and the number of adverse events (RR, 0.99; 95% CI, 0.25-1.49); however, a lower incidence of bleeding was observed (RR, 0.47; 95% CI, 0.27-0.83). Treatment with eltrombopag protected adults and children from severe disease and death.
Palavras-chave
immune thrombocytopenic purpura, erythropoietin receptors, systematic review, blood coagulation, hematologic drugs
URI
https://observatorio.fm.usp.br/handle/OPI/54995
Referências
  1. Ahmed HAW, 2021, CLIN APPL THROMB-HEM, V27, DOI 10.1177/10760296211005555
  2. [Anonymous], GRADE GUID JOUR CLIN
  3. Bussel JB, 2007, NEW ENGL J MED, V357, P2237, DOI 10.1056/NEJMoa073275
  4. Bussel JB, 2015, LANCET HAEMATOL, V2, pE315, DOI 10.1016/S2352-3026(15)00114-3
  5. Bussel JB, 2009, LANCET, V373, P641, DOI 10.1016/S0140-6736(09)60402-5
  6. Cheng G, 2011, LANCET, V377, P393, DOI 10.1016/S0140-6736(10)60959-2
  7. Cooper N, 2021, AM J HEMATOL, V96, P199, DOI 10.1002/ajh.26036
  8. Ehrlich LA, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26657
  9. Elgebaly AS, 2017, CLIN APPL THROMB-HEM, V23, P928, DOI 10.1177/1076029616663849
  10. Grainger JD, 2015, LANCET, V386, P1649, DOI 10.1016/S0140-6736(15)61107-2
  11. Huang Y T, 2018, Zhonghua Xue Ye Xue Za Zhi, V39, P32, DOI 10.3760/cma.j.issn.0253-2727.2018.01.007
  12. Kim TO, 2018, BLOOD ADV, V2, P454, DOI 10.1182/bloodadvances.2017010660
  13. Kistangari G, 2013, HEMATOL ONCOL CLIN N, V27, P495, DOI 10.1016/j.hoc.2013.03.001
  14. Kolanis Savvas, 2021, Cardiovascular & Hematological Agents in Medicinal Chemistry, V19, P83, DOI 10.2174/1871525718666200910161540
  15. Liu XF, 2022, PLATELETS, V33, P82, DOI 10.1080/09537104.2020.1847267
  16. Massaro JT, 2019, PLATELETS, V30, P828, DOI 10.1080/09537104.2019.1572873
  17. Matzdorff A, 2018, ONCOL RES TREAT, V41, P1, DOI 10.1159/000492187
  18. Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
  19. Ozelo MC, 2018, HEMATOL TRANSF CELL, V40, P50, DOI 10.1016/j.htct.2017.11.001
  20. Provan D, 2019, BLOOD ADV, V3, P3780, DOI 10.1182/bloodadvances.2019000812
  21. Gonzalez-Porras JR, 2018, THER ADV DRUG SAF, V9, P263, DOI 10.1177/2042098618769587
  22. Rodeghiero F, 2013, BLOOD, V121, P2596, DOI 10.1182/blood-2012-07-442392
  23. Siegal Deborah, 2013, Semin Hematol, V50 Suppl 1, pS18, DOI 10.1053/j.seminhematol.2013.03.005
  24. Tomiyama Y, 2012, J THROMB HAEMOST, V10, P799, DOI 10.1111/j.1538-7836.2012.04695.x
  25. Wang L, 2016, SCI REP-UK, V6, DOI 10.1038/srep39003
  26. Wong RSM, 2017, BLOOD, V130, P2527, DOI 10.1182/blood-2017-04-748707
  27. Yang RC, 2017, BRIT J HAEMATOL, V176, P101, DOI 10.1111/bjh.14380

Coleções
Artigos e Materiais de Revistas Científicas - HC/Outros